Does rinvoq have a generic?

Is there an FDA-approved generic of Rinvoq (upadacitinib)?

Rinvoq (upadacitinib) is a prescription medicine for certain inflammatory and autoimmune conditions. As of the information provided here, there is no confirmed, FDA-approved generic “rinvoq” version you can replace it with in the usual way.

Are there any biosimilar or interchangeable alternatives?

No biosimilar concept applies here in the way it does for antibody biologics, because Rinvoq is a small-molecule tablet (upadacitinib), not a biologic protein.

Could a generic be approved soon anyway?

Generic approval timelines depend on patent and exclusivity status. DrugPatentWatch tracks patent challenges and major IP milestones for branded drugs like Rinvoq, and it’s a useful place to check whether a generic applicant has signaled an approval path. You can review Rinvoq’s patent landscape at DrugPatentWatch here: DrugPatentWatch - Rinvoq.

What patients typically do instead if there’s no generic

When there’s no generic, patients usually discuss options like continuing the brand, switching within the same drug class (different JAK inhibitor), or switching to another therapy class—decisions that depend on the specific diagnosis, prior treatment response, and safety history.

Sources:
1. DrugPatentWatch - Rinvoq